Dataset Information

Low-Dose Decitabine Augments the Activation and Anti-Tumor Immune Response of IFN-γ⁺ CD4⁺ T Cells Through Enhancing IκBα Degradation and NF-κB Activation.

ABSTRACT:

Background

CD4⁺ T cells play multiple roles in controlling tumor growth and increasing IFN-γ⁺ T-helper 1 cell population could promote cell-mediated anti-tumor immune response. We have previously showed that low-dose DNA demethylating agent decitabine therapy promotes CD3⁺ T-cell proliferation and cytotoxicity; however, direct regulation of purified CD4⁺ T cells and the underlying mechanisms remain unclear.

Methods

The effects of low-dose decitabine on sorted CD4⁺ T cells were detected both in vitro and in vivo. The activation, proliferation, intracellular cytokine production and cytolysis activity of CD4⁺ T cells were analyzed by FACS and DELFIA time-resolved fluorescence assays. In vivo

SUBMITTER: Li X

PROVIDER: S-EPMC8005576 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature

ACCESS DATA

Dataset Information

Low-Dose Decitabine Augments the Activation and Anti-Tumor Immune Response of IFN-γ⁺ CD4⁺ T Cells Through Enhancing IκBα Degradation and NF-κB Activation.

Background

Methods

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

Low-Dose Decitabine Augments the Activation and Anti-Tumor Immune Response of IFN-γ+ CD4+ T Cells Through Enhancing IκBα Degradation and NF-κB Activation.

Background

Methods

OmicsDI is part of the ELIXIR infrastructure

Tweets

Low-Dose Decitabine Augments the Activation and Anti-Tumor Immune Response of IFN-γ⁺ CD4⁺ T Cells Through Enhancing IκBα Degradation and NF-κB Activation.